Samsung Biologics, the biotech arm of South Korea's Samsung Group, announced on February 4, 2026, a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to prepare for future pandemics. Through the Vaccine Manufacturing Facility Network (VMFN) agreement, CEPI gains guaranteed access to up to 50 million vaccine doses and one billion doses of drug substance. The deal bolsters CEPI's '100 Days Mission' to enhance global vaccine access.
On February 3, 2026, Samsung Biologics signed a Vaccine Manufacturing Facility Network (VMFN) partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) at a hotel in Seoul. The agreement aims to ensure rapid vaccine supply during global pandemics. Samsung Biologics will provide CEPI with guaranteed access to up to 50 million vaccine doses, plus an additional one billion doses of drug substance ready for conversion into finished products.
John Rim, president and CEO of Samsung Biologics, stated: "By working with CEPI to advance vaccine development and ensure capacity for timely production when demand rises, we aim to broaden access to high-quality vaccines for patients around the world. We will continue to apply our technical and manufacturing expertise to strengthen global preparedness."
CEPI CEO Richard Hatchett remarked: "Partnering with one of the world's leading contract manufacturers will help CEPI move more rapidly from prototype sequence to production and deliver vaccines to underserved communities worldwide."
The partnership supports CEPI's '100 Days Mission,' launched in 2022 to improve preparedness for infectious diseases like Ebola, the coronavirus, and Mpox, as well as potential future pandemics. Samsung Biologics' involvement marks a key step in expanding the international vaccine production network.
